This market research report includes a detailed segmentation of the global breast
cancer drugs market by drug type (HER2 Inhibitors, Mitotic Inhibitors, Anti-
metabolites, CDK4/6 Inhibitors, and Hormonal Receptors) and by regions (North
America, Europe, Asia Pacific, Rest of the World).
Overview of the Global Breast Cancer Drugs Market
Infoholic’s market research report predicts that the “Global Breast Cancer Drugs
Market” will grow at a CAGR of 9.4% during the forecast period 2019–2025. Breast
cancer is a kind of cancer formed in tissues of the breast. The most common types
of breast cancer are ductal carcinoma, which begins in the lining of the milk ducts
and lobular carcinoma, which starts in the lobules (milk glands) of the breast. Breast
cancer is the most common cancer among women and the second leading cause of
cancer-related deaths in women after lung cancer. Advancements in screening and
treatment for breast cancer have improved survival rates in the last few decades.
Thekeymarketplayersuseproductapprovalasoneoftheprimarystrategiestostrengthentheirpositioninthemarket.Forinstance,inMay2019,NovartisannouncedtheUSFDAapprovalforPiqrayincombinationwithfulvestrantforthetreatmentofpostmenopausalwomenandmenwithhormonereceptorpositive,PIK3CA-mutated,humanepidermalgrowthfactorreceptor-2negative(HR+/HER2-),advancedormetastaticbreastcancer.CAGR of 9.4% -2019-2025
The industry generates majority of the revenue from the key players operating in
this field; few of them include Novartis AG, F. Hoffmann-La Roche Ltd., AstraZeneca
plc, Pfizer Inc., Johnson and Johnson, Merck Co., Inc., Eli Lilly and Company, Sanofi
S.A., Bristol–Myers Squibb, AbbVie Inc., and Macrogenomics Inc.
According to the Infoholic Research analysis, North America accounted for the
largest share of the global breast cancer drugs market in 2018 and will retain a high
position during the forecast period. North America is followed by Europe, with a
share of more than 20% of the global market in 2018.
By Drug Type:
The HER2 Inhibitors segment occupied the largest share in 2018 and is expected to
grow at high-single-digit CAGR during the forecast period. The CDK4/6 inhibitors are
expected to grow at a high CAGR during the forecast period 2019–2025. Increasing
life expectancy in patients with metastatic hormone receptor (HR)-positive/human
epidermal growth factor 2 (HER2)-negative disease and a huge number of drugs in
the pipeline make it the fastest-growing segment in the next few years.
North America is dominant in the global breast cancer drugs market, followed by
Europe and Asia Pacific. The significant share of the North America market comes
from the US due to the availability of favorable reimbursement policies and the
presence of dominant vendors.
Breast Cancer Drugs Market Research Competitive Analysis – The global breast
cancer drugs market has massive growth opportunities in both developed and
developing regions. There are many new drug launches, approval, funding, and
acquisitions related to breast cancer drugs owing to the increased incidence of
breast cancer across the globe. For instance, in October 2018, FDA approved
Talzenn (talazoparib), a PARP inhibitor to treat BRCA-mutated, HER2-negative locally
advanced and metastatic breast cancer based on a trial with 431 patients where
participants who received Talzenna saw a 46% reduction in their risk of disease
progression compared with those patients who were treated only with
chemotherapy. In March 2019, AstraZeneca entered into a global development and
commercialization collaboration agreement with Daiichi Sankyo for trastuzumab
deruxtecan (DS-8201), a proprietary antibody-drug conjugate and potential new
targeted medicine for breast cancer treatment. Both the companies are currently
planning to file approval based on the successful Phase II study.
F. Hoffmann-La Roche Ltd.
Johnson and Johnson
Merck Co., Inc.
Eli Lilly and Company
Key Competitive Facts
An increase in the incidence & prevalence of breast cancer cases globally,
huge investment in R&D to develop an advanced treatment, and numerous
initiatives taken by the government to raise disease awareness are few of the
factors driving the growth of the breast cancer drugs market.
The pipeline of cancer drugs in the clinical development has expanded by
45% over the past 10 years; 87% of the late-stage pipeline is targeted
therapies, which include small molecule protein kinase inhibitors and biologic
Benefits – The report provides complete details about the sub-segments of the
breast cancer drugs market. Through this report, the key stakeholders can know
about the major trends, drivers, investments, vertical player’s initiatives, and
government initiatives toward the disease management in the upcoming years
along with details of the existing pureplay companies and new players entering the
market. Moreover, the report provides details about the major challenges that are
going to impact the market growth. Additionally, the report gives complete details
about the key business opportunities to key stakeholders in order to expand their
business and capture the revenue in specific verticals, and to analyze before
investing or expanding the business in this market.
Understanding the potential market opportunity with precise market size and
A detailed market analysis focusing on the growth of the breast cancer drugs
Factors influencing the growth of the breast cancer drugs market.
In-depth competitive analysis of dominant and pure-play vendors.
Prediction analysis of the breast cancer drugs market in both developed and
Key insights related to major segments of the breast cancer drugs market.
Latest market trend analysis impacting the buying behavior of the